We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Feb 2022
  • Code : CMI4913
  • Pages :151
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Meningococcal disease is caused by the bacterium Neisseria meningitides, which is also called as meningococcus. This disease has high mortality rate if untreated but preventable through vaccine

The global meningococcal disease treatment market is estimated to be valued at US$ 3,754.1 million in 2021 and is expected to exhibit a CAGR of 12.6% over the forecast period (2021-2028).

Figure 1. Global Meningococcal Disease Treatment Market Share (%) in Terms of Value, By Region, 2021

MENINGOCOCCAL DISEASE TREATMENT MARKET

To learn more about this report, request a free sample copy

Increasing approval of drug is expected to drive the market growth over the forecast period

For instance, in 2018, GlaxoSmithKline Plc., a pharmaceutical company has received breakthrough therapy designation from the U.S. Food and Drug Administration for Bexsero for prevention of invasive meningococcal disease in children 2-10 years of age.

Furthermore, in 2016, Pfizer Inc., a pharmaceutical company, announced that European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for its TRUMENBA (Meningococcal Group B Vaccine) for review.

TRUMENBA is developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older.

Meningococcal Disease Treatment Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 3,754.1 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 12.6% 2028 Value Projection: US$ 8,645.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Therapy Type: Antibiotics (Penicillin, Ampicillin, Chloramphenicol, Ceftriaxone), Vaccines (Bivalent, Trivalent, Tetravalent)
  • By Route of administration: Injectable and Oral
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Others
Companies covered:

GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited, F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.

Growth Drivers:
  • Approval of Drug by regulatory authority
  • Increasing prevalence of meningococcal disease 
Restraints & Challenges:
  • High cost of meningococcal vaccination

Figure 2. Global Meningococcal Disease Treatment Market Share (%), by Therapy Type, 2021

MENINGOCOCCAL DISEASE TREATMENT MARKET

To learn more about this report, request a free sample copy

Significant number of people travelling to sub-Saharan Africa is expected to propel growth of the global meningococcal disease market

Significant number of people travelling to sub-Saharan Africa is expected to propel growth of the global meningococcal vaccines market over the forecast period. According to World Economic Forum’s, 2018 report, 37.4 million tourist arrivals were recorded in Sub-Saharan Africa in 2017.

Moreover, recommendation of various regulatory bodies for meningococcal vaccination is also expected to aid in growth of the market. For instance, the Centers for Disease Control and Prevention recommends meningococcal vaccines for preteens, teens, and other people.

Global Meningococcal Disease Treatment Market– Impact of Coronavirus (Covid-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 114 million infected individuals worldwide as of March 2nd 2021.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global meningococcal disease treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing of product due to irregularities in transportation facility. Moreover, distributors are experiencing irregular demand for products from the retailers due to increasing number of patients suffering from COVID-19 and other life threatening disorders.

Global Meningococcal Disease Treatment Market Restraint

High cost of meningococcal vaccination and low coverage of the same are expected to hinder the growth of the global meningococcal vaccines market

Moreover, meningococcal vaccination is optional in several countries, which is also expected to limit the market growth.

Key Players

Major players operating in the global meningococcal disease treatment market include GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited., F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.

Frequently Asked Questions

The global meningococcal disease treatment market size is estimated to be valued at US$ 8,645.2 million in 2021 and is expected to exhibit a CAGR of 12.6% between 2021 and 2028.

Increasing approval of drug by regulatory authorities is expected to drive the market growth over the forecast period.

The market is expected to be valued at US$ 8,645.2 Mn in 2028.

North America holds the largest market share in the market

Major factors hampering the growth of the market include high cost of meningococcal vaccination.

Major players operating in the market include GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited, F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo